Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)

Publication/Presentation Date

5-2023

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Lehigh Valley Topper Cancer Institute

Document Type

Article

Share

COinS